Thomson, Bart R. http://orcid.org/0000-0002-3073-9821
Schwendinger, Nina
Beckmann, Katrin http://orcid.org/0000-0002-1823-7845
Gentinetta, Thomas
Couto, Daniel
Wymann, Sandra
Verdon, Valérie
Buzzi, Raphael M. http://orcid.org/0000-0002-9584-3590
Akeret, Kevin http://orcid.org/0000-0002-5946-4999
Kronen, Peter W.
Weinberger, Eva M.
Held, Ulrike http://orcid.org/0000-0003-3105-5840
Seehusen, Frauke http://orcid.org/0000-0001-6701-7868
Richter, Henning http://orcid.org/0000-0003-3696-6993
Schaer, Dominik J. http://orcid.org/0000-0002-6468-4013
Hugelshofer, Michael http://orcid.org/0000-0002-3057-0472
Funding for this research was provided by:
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (197823, 197823)
Innosuisse - Schweizerische Agentur für Innovationsförderung (19300.1, 19300.1)
Uniscientia Foundation (174-2020, 174-2020)
University of Zurich
Article History
Received: 3 January 2024
Revised: 10 April 2024
Accepted: 15 April 2024
First Online: 23 April 2024
Declarations
:
: This study was conducted according to the Swiss Animal Welfare Act (TschG, 2005) and the Swiss Animal Welfare Ordinance (TSchV, 2008) received ethical approval from the Swiss Federal Veterinary Office Zurich (animal license no. ZH171/2020).
: Some authors are inventors on haptoglobin-related patent applications: WO2020/234195 (MH, DJS), PCT/EP2022/052203 (MH, DJS, RMB, KA). MH is consulting CSL Behring AG as expert advisor and received consulting honoraria. Some authors are employees of CSL Behring Switzerland AG (TG, DC, SW, VV) and are involved in a drug development program for the therapeutic use of CSL888 in aSAH patients.